/
Gastroenterology
Cirrhosis
57
Pipeline Programs↗
92
Active Trials↗
49
Companies Involved↗
Cirrhosis is a moderately active landscape with 57 programs across 49 companies. The most active players are Sanofi, Boryung Pharmaceutical Co., Ltd. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical43
Phase 25
Phase 37
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
51 of 54 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 100% of 57 pipeline programs.
Analysis
Trial Status
360
clinical trials
Completed156 · 43%
Unknown status77 · 21%
Recruiting52 · 14%
Not yet recruiting30 · 8%
Terminated22 · 6%
Withdrawn11 · 3%
Other12 · 3%
Clinical Trials
Trial Activity
360 trials
Page 1 of 24
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)